Pfizer Inc. - PFE STOCK NEWS

Pfizer invites investors and the public to its conference call on May 4, 2021, at 10 a.m. EDT. This call aims to discuss the First Quarter 2021 Performance Report. Interested participants can join via phone at (833) 711-4984 or (916) 900-3769, using the password 'First Quarter Earnings'. The report and webcast details are available at www.pfizer.com/investors. Pfizer is dedicated to improving global health through innovative medicines and vaccines, demonstrating its commitment for over 170 years.

The Israel Ministry of Health, Pfizer, and BioNTech announced significant findings from a real-world study showing a 97% effectiveness of the Pfizer-BioNTech COVID-19 Vaccine in preventing symptomatic COVID-19, severe cases, and deaths. This data, derived from health surveillance from January to March 2021, showcases the impact of Israel's vaccination efforts, particularly against the B.1.1.7 variant. Further, the vaccine demonstrated 94% effectiveness against asymptomatic infections, emphasizing its role in controlling the pandemic and supporting ongoing immunization campaigns globally.

Pfizer (NYSE: PFE) will host a webcast featuring CFO Frank D’Amelio at the Barclays Global Healthcare Conference on March 11, 2021, at 1:15 p.m. EST. Investors and the public can access the discussion via www.pfizer.com/investors. The archived recording will also be available on the same site after the event. Pfizer aims to enhance health care through innovative medicines and vaccines, maintaining a commitment to quality and safety in the biopharmaceutical industry for over 170 years.

The FDA has approved Pfizer's LORBRENA (lorlatinib) for first-line treatment of ALK-positive non-small cell lung cancer (NSCLC), expanding its indication for adults with metastatic disease. LORBRENA's transition from accelerated to full approval is based on the pivotal Phase 3 CROWN trial, which demonstrated a 72% reduction in progression or death compared to XALKORI. The drug targets common tumor mutations and is effective against brain metastases, presenting high response rates. Serious adverse events occurred in 34% of patients, with a 3.4% fatality rate.

Strata Oncology, Inc., a precision oncology firm, has launched the Strata PATH trial, a multi-drug and biomarker-driven clinical trial aimed at evaluating the effectiveness of FDA-approved therapies for specific cancer biomarkers. Pfizer (NYSE: PFE) will supply targeted drugs at no cost to participants. The trial is designed for patients with advanced solid tumors who have exhausted standard treatments. It utilizes Strata's comprehensive genomic profiling to match patients with investigational therapies, aiming to accelerate cancer treatment availability.

Pfizer announced the European Medicines Agency's acceptance of its Marketing Authorization Application for the 20-valent pneumococcal conjugate vaccine (20vPnC) targeting invasive disease and pneumonia in adults 18 and older. The review process by the Committee for Medicinal Products for Human Use begins, based on clinical data from over 6,000 participants in multiple trials. The 20vPnC vaccine addresses significant pneumococcal disease serotypes not included in existing vaccines, demonstrating Pfizer's ongoing commitment to vaccine innovation.

Pfizer (NYSE: PFE) and OPKO Health (NASDAQ: OPK) announced that the European Medicines Agency (EMA) has validated the Marketing Authorization Application for somatrogon, a long-acting growth hormone for treating pediatric patients with growth hormone deficiency (GHD). If approved, somatrogon will allow once-weekly administration, reducing daily injection burdens. Results from a global Phase 3 trial showed somatrogon met its primary endpoint of height velocity non-inferiority compared to daily somatropin. A European Commission decision is anticipated in 2022.

Pfizer (NYSE: PFE) and BioNTech (Nasdaq: BNTX) are evaluating a third dose of their COVID-19 vaccine, BNT162b2, to assess safety and immunity against circulating and emerging SARS-CoV-2 variants. This study will involve participants from a previous Phase 1 trial, who will receive the booster 6 to 12 months post-initial vaccination. Additionally, the companies are in talks with the FDA and EMA for a clinical study on a variant-specific vaccine. The goal is to ensure preparedness against future variants while maintaining current vaccine effectiveness.

Seven Bridges is partnering with Pfizer (NYSE: PFE) to enhance the management of single-cell RNA sequencing (scRNASeq) data. This collaboration aims to optimize Pfizer's cloud capabilities and data analysis through the cloud-based Seven Bridges Platform, which will handle terabytes of scRNASeq data and improve the understanding of gene expression. The initiative is expected to streamline data accessibility and reduce costs associated with sequencing data, bolstering Pfizer's research and development efforts in drug discovery.